{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:15:02Z","timestamp":1790712902084,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T00:00:00Z","timestamp":1644624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T00:00:00Z","timestamp":1644624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Musculoskelet Surg"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s12306-022-00738-x","type":"journal-article","created":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T15:02:49Z","timestamp":1644678169000},"page":"7-18","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Clinical outcomes of medical treatments for progressive desmoid tumors following active surveillance: a systematic review"],"prefix":"10.1007","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8419-2008","authenticated-orcid":false,"given":"S.","family":"Tsukamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Takahama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. F.","family":"Mavrogenis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Errani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,12]]},"reference":[{"key":"738_CR1","unstructured":"Fritchie KJ, Crago AM, van de Rijn M (2020) Desmoid fibromatosis. In: The WHO classification of tumours editorial board (Ed.) WHO classification of tumours. 5th edn. Soft tissue and bone tumours. IARC, Lyon, pp 93\u201395"},{"key":"738_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejca.2014.11.005","volume":"51","author":"B Kasper","year":"2015","unstructured":"Kasper B, Baumgarten C, Bonvalot S et al (2015) Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients\u2019 and professionals\u2019 expertise - a sarcoma patients EuroNet and European organisation for research and treatment of cancer\/soft tissue and bone sarcoma group initiative. Eur J Cancer 51:127\u2013136. https:\/\/doi.org\/10.1016\/j.ejca.2014.11.005","journal-title":"Eur J Cancer"},{"key":"738_CR3","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1245\/s10434-009-0586-2","volume":"16","author":"M Fiore","year":"2009","unstructured":"Fiore M, Rimareix F, Mariani L et al (2009) Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol 16:2587\u20132593. https:\/\/doi.org\/10.1245\/s10434-009-0586-2","journal-title":"Ann Surg Oncol"},{"key":"738_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejca.2017.06.017","volume":"83","author":"N Penel","year":"2017","unstructured":"Penel N, Le Cesne A, Bonvalot S et al (2017) Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: a nationwide prospective cohort from the French Sarcoma Group. Eur J Cancer 83:125\u2013131. https:\/\/doi.org\/10.1016\/j.ejca.2017.06.017","journal-title":"Eur J Cancer"},{"key":"738_CR5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S2352-4642(17)30045-7","volume":"1","author":"D Orbach","year":"2017","unstructured":"Orbach D, Brennan B, Bisogno G et al (2017) The EpSSG NRSTS 2005 treatment protocol for desmoid-type fibromatosis in children: an international prospective case series. Lancet Child Adolesc Health 1:284\u2013292. https:\/\/doi.org\/10.1016\/S2352-4642(17)30045-7","journal-title":"Lancet Child Adolesc Health"},{"key":"738_CR6","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1093\/annonc\/mdx323","volume":"28","author":"B Kasper","year":"2017","unstructured":"Kasper B, Baumgarten C, Garcia J et al (2017) An update on the management of sporadic desmoid-type fibromatosis: a European consensus initiative between Sarcoma PAtients EuroNet (SPAEN) and European organization for research and treatment of cancer (EORTC)\/soft tissue and bone sarcoma group (STBSG). Ann Oncol 28:2399\u20132408. https:\/\/doi.org\/10.1093\/annonc\/mdx323","journal-title":"Ann Oncol"},{"key":"738_CR7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ejca.2019.11.013","volume":"127","author":"Desmoid Tumor Working Group","year":"2020","unstructured":"Desmoid Tumor Working Group (2020) The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer 127:96\u2013107. https:\/\/doi.org\/10.1016\/j.ejca.2019.11.013","journal-title":"Eur J Cancer"},{"key":"738_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"738_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"738_CR10","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm. Accessed 30 Nov 2020"},{"key":"738_CR11","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jclinepi.2012.09.016","volume":"66","author":"SY Kim","year":"2013","unstructured":"Kim SY, Park JE, Lee YJ et al (2013) Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol 66:408\u2013414. https:\/\/doi.org\/10.1016\/j.jclinepi.2012.09.016","journal-title":"J Clin Epidemiol"},{"key":"738_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"738_CR13","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa1805052","volume":"379","author":"MM Gounder","year":"2018","unstructured":"Gounder MM, Mahoney MR, Van Tine BA et al (2018) Sorafenib for advanced and refractory desmoid tumors. N Engl J Med 379:2417\u20132428. https:\/\/doi.org\/10.1056\/NEJMoa1805052","journal-title":"N Engl J Med"},{"key":"738_CR14","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S1470-2045(19)30276-1","volume":"20","author":"M Toulmonde","year":"2019","unstructured":"Toulmonde M, Pulido M, Ray-Coquard I et al (2019) Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol 20:1263\u20131272. https:\/\/doi.org\/10.1016\/S1470-2045(19)30276-1","journal-title":"Lancet Oncol"},{"key":"738_CR15","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1200\/JCO.1998.16.9.3021","volume":"16","author":"SX Skapek","year":"1998","unstructured":"Skapek SX, Hawk BJ, Hoffer FA et al (1998) Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid tumor in children. J Clin Oncol 16:3021\u20133027. https:\/\/doi.org\/10.1200\/JCO.1998.16.9.3021","journal-title":"J Clin Oncol"},{"key":"738_CR16","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/1097-0142(20010901)92:5<1259::aid-cncr1446>3.0.co;2-y","volume":"92","author":"A Azzarelli","year":"2001","unstructured":"Azzarelli A, Gronchi A, Bertulli R et al (2001) Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 92:1259\u20131264. https:\/\/doi.org\/10.1002\/1097-0142(20010901)92:5%3c1259::aid-cncr1446%3e3.0.co;2-y","journal-title":"Cancer"},{"key":"738_CR17","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3109\/0284186X.2010.509105","volume":"50","author":"A Constantinidou","year":"2011","unstructured":"Constantinidou A, Jones RL, Scurr M et al (2011) Advanced aggressive fibromatosis: effective palliation with chemotherapy. Acta Oncol 50:455\u2013461. https:\/\/doi.org\/10.3109\/0284186X.2010.509105","journal-title":"Acta Oncol"},{"key":"738_CR18","doi-asserted-by":"publisher","first-page":"455","DOI":"10.21147\/j.issn.1000-9604.2017.05.10","volume":"29","author":"S Li","year":"2017","unstructured":"Li S, Fan Z, Fang Z et al (2017) Efficacy of vinorelbine combined with low-dose methotrexate for treatment of inoperable desmoid tumor and prognostic factor analysis. Chin J Cancer Res 29:455\u2013462","journal-title":"Chin J Cancer Res"},{"key":"738_CR19","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1002\/cam4.2374","volume":"8","author":"KM Ingley","year":"2019","unstructured":"Ingley KM, Burtenshaw SM, Theobalds NC et al (2019) Clinical benefit of methotrexate plus vinorelbine chemotherapy for desmoid fibromatosis (DF) and correlation of treatment response with MRI. Cancer Med 8:5047\u20135057. https:\/\/doi.org\/10.1002\/cam4.2374","journal-title":"Cancer Med"},{"key":"738_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14626","author":"Y Nishida","year":"2020","unstructured":"Nishida Y, Hamada S, Urakawa H et al (2020) Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: a phase II clinical trial. Cancer Sci. https:\/\/doi.org\/10.1111\/cas.14626","journal-title":"Cancer Sci"},{"key":"738_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000604","author":"A Napolitano","year":"2020","unstructured":"Napolitano A, Provenzano S, Colombo C et al (2020) Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. ESMO Open. https:\/\/doi.org\/10.1136\/esmoopen-2019-000604","journal-title":"ESMO Open"},{"key":"738_CR22","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.25089","volume":"116","author":"VP de Camargo","year":"2010","unstructured":"de Camargo VP, Keohan ML, D\u2019Adamo DR et al (2010) Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer 116:2258\u20132265. https:\/\/doi.org\/10.1002\/cncr.25089","journal-title":"Cancer"},{"key":"738_CR23","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1007\/s00259-010-1498-x","volume":"37","author":"B Kasper","year":"2010","unstructured":"Kasper B, Dimitrakopoulou-Strauss A, Strauss LG, Hohenberger P (2010) Positron emission tomography in patients with aggressive fibromatosis\/desmoid tumours undergoing therapy with imatinib. Eur J Nucl Med Mol Imag 37:1876\u20131882. https:\/\/doi.org\/10.1007\/s00259-010-1498-x","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"738_CR24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/annonc\/mdq341","volume":"22","author":"N Penel","year":"2011","unstructured":"Penel N, Le Cesne A, Bui BN et al (2011) Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC\/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol 22:452\u2013457. https:\/\/doi.org\/10.1093\/annonc\/mdq341","journal-title":"Ann Oncol"},{"key":"738_CR25","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/389672","volume":"2013","author":"B Kasper","year":"2013","unstructured":"Kasper B, Dimitrakopoulou-Strauss A, Pilz LR et al (2013) Positron emission tomography as a surrogate marker for evaluation of treatment response in patients with desmoid tumors under therapy with imatinib. Biomed Res Int 2013:389672. https:\/\/doi.org\/10.1155\/2013\/389672","journal-title":"Biomed Res Int"},{"key":"738_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejca.2017.02.001","volume":"76","author":"B Kasper","year":"2017","unstructured":"Kasper B, Gruenwald V, Reichardt P et al (2017) Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). Eur J Cancer 76:60\u201367. https:\/\/doi.org\/10.1016\/j.ejca.2017.02.001","journal-title":"Eur J Cancer"},{"key":"738_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26968","volume":"65","author":"L Agresta","year":"2018","unstructured":"Agresta L, Kim H, Turpin BK et al (2018) Pazopanib therapy for desmoid tumors in adolescent and young adult patients. Pediatr Blood Cancer 65:e26968. https:\/\/doi.org\/10.1002\/pbc.26968","journal-title":"Pediatr Blood Cancer"},{"key":"738_CR28","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.1158\/1078-0432.CCR-10-3322","volume":"17","author":"MM Gounder","year":"2011","unstructured":"Gounder MM, Lefkowitz RA, Keohan ML et al (2011) Activity of Sorafenib against desmoid tumor\/deep fibromatosis. Clin Cancer Res 17:4082\u20134090. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-3322","journal-title":"Clin Cancer Res"},{"key":"738_CR29","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.2147\/DDDT.S271008","volume":"14","author":"C Zheng","year":"2020","unstructured":"Zheng C, Zhou Y, Wang Y et al (2020) The activity and safety of anlotinib for patients with extremity desmoid fibromatosis: a retrospective study in a single institution. Drug Des Devel Ther 14:3941\u20133950. https:\/\/doi.org\/10.2147\/DDDT.S271008","journal-title":"Drug Des Devel Ther"},{"key":"738_CR30","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/BF02055435","volume":"40","author":"M Schnitzler","year":"1997","unstructured":"Schnitzler M, Cohen Z, Blackstein M et al (1997) Chemotherapy for desmoid tumors in association with familial adenomatous polyposis. Dis Colon Rectum 40:798\u2013801. https:\/\/doi.org\/10.1007\/BF02055435","journal-title":"Dis Colon Rectum"},{"key":"738_CR31","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1007\/BF02234783","volume":"44","author":"LS Poritz","year":"2001","unstructured":"Poritz LS, Blackstein M, Berk T et al (2001) Extended follow-up of patients treated with cytotoxic chemotherapy for intra-abdominal desmoid tumors. Dis Colon Rectum 44:1268\u20131273. https:\/\/doi.org\/10.1007\/BF02234783","journal-title":"Dis Colon Rectum"},{"key":"738_CR32","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1200\/JCO.2005.02.1923","volume":"24","author":"M Gega","year":"2006","unstructured":"Gega M, Yanagi H, Yoshikawa R et al (2006) Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 24:102\u2013105. https:\/\/doi.org\/10.1200\/JCO.2005.02.1923","journal-title":"J Clin Oncol"},{"key":"738_CR33","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/j.ejca.2008.06.038","volume":"44","author":"MM Bertagnolli","year":"2008","unstructured":"Bertagnolli MM, Morgan JA, Fletcher CDM et al (2008) Multimodality treatment of mesenteric desmoid tumours. Eur J Cancer 44:2404\u20132410. https:\/\/doi.org\/10.1016\/j.ejca.2008.06.038","journal-title":"Eur J Cancer"},{"key":"738_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26375","author":"P Ananth","year":"2017","unstructured":"Ananth P, Werger A, Voss S et al (2017) Liposomal doxorubicin: Effective treatment for pediatric desmoid fibromatosis. Pediatr Blood Cancer. https:\/\/doi.org\/10.1002\/pbc.26375","journal-title":"Pediatr Blood Cancer"},{"key":"738_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27472","volume":"66","author":"A Ferrari","year":"2019","unstructured":"Ferrari A, Orbach D, Affinita MC et al (2019) Evidence of hydroxyurea activity in children with pretreated desmoid-type fibromatosis: a new option in the armamentarium of systemic therapies. Pediatr Blood Cancer 66:e27472. https:\/\/doi.org\/10.1002\/pbc.27472","journal-title":"Pediatr Blood Cancer"},{"key":"738_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/ONCO.13516","author":"S Gennatas","year":"2020","unstructured":"Gennatas S, Chamberlain F, Smrke A et al (2020) A timely oral option: single-agent vinorelbine in desmoid tumors. Oncologist. https:\/\/doi.org\/10.1002\/ONCO.13516","journal-title":"Oncologist"},{"key":"738_CR37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejca.2020.06.022","volume":"137","author":"MJM Timbergen","year":"2020","unstructured":"Timbergen MJM, Schut A-RW, Gr\u00fcnhagen DJ et al (2020) Active surveillance in desmoid-type fibromatosis: a systematic literature review. Eur J Cancer 137:18\u201329. https:\/\/doi.org\/10.1016\/j.ejca.2020.06.022","journal-title":"Eur J Cancer"},{"key":"738_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyz204","author":"K Shimizu","year":"2019","unstructured":"Shimizu K, Hamada S, Sakai T et al (2019) Efficacy of low-dose chemotherapy with methotrexate and vinblastine for patients with extra-abdominal desmoid-type fibromatosis: a systematic review. Jpn J Clin Oncol. https:\/\/doi.org\/10.1093\/jjco\/hyz204","journal-title":"Jpn J Clin Oncol"},{"key":"738_CR39","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1093\/jjco\/hyaa125","volume":"50","author":"K Shimizu","year":"2020","unstructured":"Shimizu K, Kawashima H, Kawai A et al (2020) Effectiveness of doxorubicin-based and liposomal doxorubicin chemotherapies for patients with extra-abdominal desmoid-type fibromatosis: a systematic review. Jpn J Clin Oncol 50:1274\u20131281. https:\/\/doi.org\/10.1093\/jjco\/hyaa125","journal-title":"Jpn J Clin Oncol"},{"key":"738_CR40","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1245\/s10434-018-6408-7","volume":"25","author":"K Smith","year":"2018","unstructured":"Smith K, Desai J, Lazarakis S, Gyorki D (2018) Systematic review of clinical outcomes following various treatment options for patients with extraabdominal desmoid tumors. Ann Surg Oncol 25:1544\u20131554. https:\/\/doi.org\/10.1245\/s10434-018-6408-7","journal-title":"Ann Surg Oncol"},{"key":"738_CR41","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/annonc\/mdg064","volume":"14","author":"J Janinis","year":"2003","unstructured":"Janinis J, Patriki M, Vini L et al (2003) The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol 14:181\u2013190. https:\/\/doi.org\/10.1093\/annonc\/mdg064","journal-title":"Ann Oncol"},{"key":"738_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33233","author":"B Kasper","year":"2020","unstructured":"Kasper B, Raut CP, Gronchi A (2020) Desmoid tumors: to treat or not to treat, that is the question. Cancer. https:\/\/doi.org\/10.1002\/cncr.33233","journal-title":"Cancer"},{"key":"738_CR43","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.mayocp.2017.02.012","volume":"92","author":"KM Skubitz","year":"2017","unstructured":"Skubitz KM (2017) Biology and treatment of aggressive fibromatosis or desmoid tumor. Mayo Clin Proc 92:947\u2013964. https:\/\/doi.org\/10.1016\/j.mayocp.2017.02.012","journal-title":"Mayo Clin Proc"},{"key":"738_CR44","first-page":"139","volume":"295","author":"E Buchdunger","year":"2000","unstructured":"Buchdunger E, Cioffi CL, Law N et al (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139\u2013145","journal-title":"J Pharmacol Exp Ther"},{"key":"738_CR45","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1182\/blood.V90.12.4947","volume":"90","author":"M Carroll","year":"1997","unstructured":"Carroll M, Ohno-Jones S, Tamura S et al (1997) CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90:4947\u20134952","journal-title":"Blood"},{"key":"738_CR46","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L et al (2004) BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099\u20137109. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-1443","journal-title":"Cancer Res"},{"key":"738_CR47","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s11684-018-0672-6","volume":"13","author":"Z Wang","year":"2019","unstructured":"Wang Z, Wu J, Tian X, Hao C (2019) Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects. Front Med 13:427\u2013437. https:\/\/doi.org\/10.1007\/s11684-018-0672-6","journal-title":"Front Med"},{"key":"738_CR48","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","volume":"94","author":"E Weisberg","year":"2006","unstructured":"Weisberg E, Manley P, Mestan J et al (2006) AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 94:1765\u20131769. https:\/\/doi.org\/10.1038\/sj.bjc.6603170","journal-title":"Br J Cancer"},{"key":"738_CR49","doi-asserted-by":"publisher","first-page":"6977","DOI":"10.1016\/j.bmc.2010.08.026","volume":"18","author":"PW Manley","year":"2010","unstructured":"Manley PW, Stiefl N, Cowan-Jacob SW et al (2010) Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg Med Chem 18:6977\u20136986. https:\/\/doi.org\/10.1016\/j.bmc.2010.08.026","journal-title":"Bioorg Med Chem"},{"key":"738_CR50","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.bbapap.2009.11.008","volume":"1804","author":"PW Manley","year":"2010","unstructured":"Manley PW, Drueckes P, Fendrich G et al (2010) Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 1804:445\u2013453. https:\/\/doi.org\/10.1016\/j.bbapap.2009.11.008","journal-title":"Biochim Biophys Acta"},{"key":"738_CR51","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","volume":"9","author":"Y Sun","year":"2016","unstructured":"Sun Y, Niu W, Du F et al (2016) Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol 9:105. https:\/\/doi.org\/10.1186\/s13045-016-0332-8","journal-title":"J Hematol Oncol"},{"key":"738_CR52","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1159\/000081337","volume":"27","author":"G Wehl","year":"2004","unstructured":"Wehl G, Rossler J, Otten JE et al (2004) Response of progressive fibromatosis to therapy with liposomal doxorubicin. Onkologie 27:552\u2013556. https:\/\/doi.org\/10.1159\/000081337","journal-title":"Onkologie"},{"key":"738_CR53","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1016\/j.ejca.2009.08.016","volume":"45","author":"A Constantinidou","year":"2009","unstructured":"Constantinidou A, Jones RL, Scurr M et al (2009) Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer 45:2930\u20132934. https:\/\/doi.org\/10.1016\/j.ejca.2009.08.016","journal-title":"Eur J Cancer"},{"key":"738_CR54","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMct0708272","volume":"358","author":"OS Platt","year":"2008","unstructured":"Platt OS (2008) Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med 358:1362\u20131369. https:\/\/doi.org\/10.1056\/NEJMct0708272","journal-title":"N Engl J Med"},{"key":"738_CR55","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1158\/1078-0432.CCR-14-0607","volume":"21","author":"WA Messersmith","year":"2015","unstructured":"Messersmith WA, Shapiro GI, Cleary JM et al (2015) A Phase I, dose-finding study in patients with advanced solid malignancies of the oral \u03b3-secretase inhibitor PF-03084014. Clin Cancer Res 21:60\u201367. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0607","journal-title":"Clin Cancer Res"}],"container-title":["MUSCULOSKELETAL SURGERY"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12306-022-00738-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12306-022-00738-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12306-022-00738-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T03:13:26Z","timestamp":1679022806000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12306-022-00738-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,12]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["738"],"URL":"https:\/\/doi.org\/10.1007\/s12306-022-00738-x","relation":{},"ISSN":["2035-5106","2035-5114"],"issn-type":[{"value":"2035-5106","type":"print"},{"value":"2035-5114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,12]]},"assertion":[{"value":"7 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}